The European Medicines Agency (EMA) has denied approval for lecanemab, a drug being currently developed to help against Alzheimer’s. It has been reported that the drug has been showing the ability to start slowing cognitive decline. However, the EMA also concluded that there are indeed some risks and also possible severe side effects such as brain bleeding and swelling.
View Original Article
RetailWire is retailing’s premier online discussion forum, serving the industry as a free resource for over 18 years with compelling content that goes well beyond conventional headline reporting. Each business morning, our editors post timely topics worthy of commentary by the RetailWire BrainTrust panel of industry experts and general readership. The results are virtual round tables of industry opinion and advice covering the most dynamic trends and issues affecting the retailing industry.
https://retailwire.com/
Do you like RetailWire's articles? Follow on social!